235 results about "L-Pyroglutamic Acid" patented technology

The disclosure relates to a method for preparing a compound of formula (I), wherein P₁ and P₂ are groups protecting the carboxylic acid and oxyamine functions, starting from pyroglutamic acid (S). The disclosure also relates to novel intermediates.

Glutamic acid derivatives, in particular monatin, may be conveniently prepared by alkylating a 4-protected hydroxyl pyroglutamic acid derivative with an alkylating agent to prepare a 4-protected hydroxyl-4-alkylglutamic acid derivative, followed by the steps of hydrolysis and deprotection. The 4-protected hydroxyl pyroglutamic acid derivative is easy to produce from hydroxyproline. The 4-protected hydroxyl pyroglutamic acid derivative is particularly suitable for use in the efficient manufacture of monatin of high optical purity, since it can be alkylated selectively at the 4-position and stereoselectively and after its alkylation, it can easily be converted to a glutamic acid derivative.

The present invention provides formulas for producing compositions for the structural/functional nutritional support for those who struggle with poor focus, concentration and/or memory. In addition, the present invention provides compositions comprising nutritional/botanical factors helpful to those who subjectively experience transient mental fatigue or poor cognitive function. The compositions of this invention consist primarily of the following ingredients B-complex vitamins, antioxidants, minerals, phosphatidyl serine (PS), choline, dimenthyl-aminoethanol (DMAE), docosahexaenoic acid (DHA), L-pyroglutamic acid, as well as herbal extracts from Bacopa monniera, Vinca minor, and Huperzia serrata. The present invention also relates to the administration of these compounds to alleviate mental fatigue or poor cognitive function.

Vitamin E conjugates, methods for their preparation, and compositions that include the conjugates. The vitamin E conjugates include a tocopherol moiety covalently coupled through a linker moiety to either a pyroglutamate moiety, a pyrrolidinone moiety, or a gentisic acid moiety.

The invention discloses a synthesis method of pidotimod. The synthesis method comprises the following steps: reacting L-cysteine with paraformaldehyde or formaldehyde to generate L-thiazolidine-4-carboxylic acid, performing esterification to generate L-thiazolidine-4-carboxylate, or reacting L-cysteine ester hydrochloride with paraformaldehyde or formaldehyde to generate L-thiazolidine-4-carboxylate; and then carrying out condensation reaction on L-thiazolidine-4-carboxylate and L-pyroglutamic acid to generate (4R)-3-[[(2S)-5-oxo-2-pyrrolidinyl]carbonyl]-4-thiazolidine carboxylate, and then synthesizing pidotimod through hydrolysis reaction. Compared with the prior art, the technology in the invention is simple, is easy to operate, has high product yield and low production cost, is environmentally friendly and is suitable for industrial production.

A method for conversion of an N-terminal glutamine and/or glutamic acid residue of a protein to pyro-glutamic acid within a purification process.

The invention relates to a method for synthesizing pyroglutamic calcium glutamate with shells serving as calcium sources. Processing steps comprise shell pretreatment, synthesis, crystallization and drying. The method includes immersing the shells with 0.05M hydrochloric acid, drying, smashing and processing the shells with elutriation to obtain calcium shell powder, compounding pyroglutamic acid with the shell powder (the calciumcontent of calcium carbonate is calculated by 95%) according to a molar ratio of 2: (1.0-1.2), adding distilled water 20 to 25 times of the weight of the shell powder, stirring and heating the mixture to 55 DEG C to 60 DEG C, keeping the temperature for 1.5 to 2.0 hours, and performing cooling and suction filtration; performing pressure reduction and concentration on the obtained filtrate to enable the volume to be1/10, adding 95% of edible alcohol until the ethanol saturation degree is 90%, performing stirring, standing and filtering; and performing suction filtration, and drying the obtain crystals in a drying oven of 90 DEG C to obtain the pyroglutamic calcium glutamate product. According to the method, the process is simple, the product water solubility is good, various shells can be utilized highly, and the product can serve as calcium supplement, dietary supplement for improving the brain health level and the like.

The disclosure provides a method for synthesizing free base forms of (2R,6R)-hydroxynorketamine (HNK) and (2S,6S)-hydroxynorketamine. In an embodiment synthesis of (2R,6R)-hydroxynorketamine (HNK) includes preparation of (R)-norketamine via chiral resolution from racemic norketamine via a chiral resolution with L-pyroglutamic acid. The disclosure also provided crystal forms of the corresponding (2R,6R)-hydroxynorketamine (HNK) and (2S,6S)-hydroxynorketamine hydrochloride salts.

The invention discloses a process for producing pidotimod and belongs to the technical field of medicines. A pidotimod crude product is prepared by a one-pot method which mainly comprises the following steps: (1) in the presence of a condensing agent as a catalyst, carrying out condensation reaction on L-pyroglutamic acid and L-4-thiazolidine formate to produce pidotimod ester and after the reaction is completed, filtering solid to obtain a mother liquid; and (2) adding an appropriate amount of acid into the mother liquid for hydrolyzing pidotimod ester, after the reaction is completed, separating liquid, retaining an aqueous phase, precipitating solids in an ice bath and filtering to obtain pidotimod. The yield is greatly increased, the process is simple, no special device is needed and pidotimod is suitable for large-scale production. According to the preparation process of pidotimod, by preferably selecting the process parameters, the yield and purity are greatly improved. Compared with the prior art, the yield of the pharmaceutical-grade pidotimod pure product is increased by 10-20%.

The invention discloses a method for preparing magnesium L-pyroglutamate. The preparation process is as follows: a, preparing L-pyroglutamic acid by dehydration, wherein L-glutamic acid and deionized water are put into a reaction kettle, stirred, heated to 100 to 128 DEG C and kept at the temperature for 6 to 12 hours; b, separating and extracting the L-pyroglutamic acid, wherein after pyrogenation is finished, the reaction solution is cooled to room temperature, deionized water is added to dilute the reaction solution, and the L-pyroglutamic acid and the non-pyrolyzed L-glutamic acid are separated by a cation exchange resin column; c, preparing the magnesium L-pyroglutamate, wherein the solution of the L-pyroglutamic acid obtained by the step b is stirred and heated and added with magnesium carbonate or magnesium oxide; and d, separating and extracting the magnesium L-pyroglutamate, wherein a sample is made after the reaction solution obtained by the step c is clear to test the pH value of the reaction solution, the pH value of the reaction solution is adjusted to 6.5 to 7.5, the reaction solution is concentrated till supersaturated solution is obtained, the supersaturated solution is stirred and cooled for crystallization, the solution is subjected to vacuum filtration and the crystals are subjected to vacuum drying to obtain the magnesium L-pyroglutamate. The method is simple in operation, high production efficiency and low in cost and is suitable for industrial production.

Providing a hydrated food which contains theanine and in which theanine content can stably be maintained even when the hydrated food is preserved for a long period of time and the taste threshold of the food can be improved and the peculiar taste can be flavored. The problem can be overcome by a hydrated food containing theanine and pyroglutamic acid. In this case, it is preferable that pH ranges from about 2.8 to about 7.5. Furthermore, it is preferable that a content of pyroglutamic acid ranges from about 1% to about 20% relative to a content of theanine.

The invention discloses a preparation method of an inflaming retarding type aqueous polyurethane coating. Under the condition that dibutylboron trifluoromethanesulfonate catalysts exist, 1,4-Bis(hydroxydimethylsily)benzene and hexamethylene diisocyanate are mixed by a weight ratio of 2:1 and react for 2-4 hours at 80-110 DEG C, then parathion is added into a reaction system, the reaction temperature is 80-110 DEG C, the reaction time is 40-60 minutes, and a polyurethane prepolymer is obtained; chain extenders and butanone are added into the polyurethane prepolymer and are stirred for 3-5 hours at 65-85 DEG C, trithylamine is added for neutral reaction for 10-40 minutes, water is added for emulsification, and aqueous polyurethane is formed; aluminum salt dispersion liquid, L-pyroglutamic acid, screw ring phosphoryl nafoxidine ester and N-aminoethyl-3-aminopropyl triethoxysilane are added into the aqueous polyurethane and are sheared and stirred for 40-80 minutes under the condition of pH being 7, and the inflaming retarding type aqueous polyurethane coating is obtained. The flammability and mechanical property of the obtained polyurethane coating are greatly improved.

The invention provides an anti-platelet aggregation optically active polypeptide compound. The compound consists of three amino acids, namely levorotatory or dextrorotatory tryptophan, asparagine and pyroglutamic acid, and is used for treating platelet aggregation-related heart cerebrovascular diseases, such as ischemic stroke, inflammation, asthma and the like.